{‘She has little qualifications’: this US medical establishment prepares for Høeg's tenure at the FDA.

Given that the United States proceeds with historic changes to its vaccination schedules, a particular individual appears somewhat surprisingly: Høeg, a US-based sports medicine doctor and public health researcher who initially gained attention by casting doubt on coronavirus vaccines during the pandemic and has concentrated on potential deaths after Covid vaccination in her short time at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Vaccine Schedule

Health officials planned to reveal major revisions to the pediatric immunization program earlier this month, synchronizing the US with the Danish immunization schedule, it is understood – a major change that would place the US at odds with much of the global community with insufficient data for public health gain. The announcement has been delayed until the coming year.

In place of the director of the vaccine center, Dr. Høeg is set to address the audience at the event. She was just designated acting director of the FDA’s CDER, the fifth person to head the center this calendar year.

Consolidating Power at the Agency

The acting appointment could signify a tighter collaboration between the drug and vaccine branches as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it suggests a renewed priority upon dismantling long-standing vaccines at the FDA.

The new acting director has repeatedly called for discontinuing specific childhood vaccine recommendations in the US so as to align more like Denmark's approach, a society with nationalized medicine and a population about the population of the state of Wisconsin.

So far comments, she has continued to focus on immunizations – typically the domain of Prasad, chief of the FDA’s vaccine center – rather than medication approval.

Doubts Over Background

Høeg has no obvious track record in drug development, regulation or administrative roles, which has been customary for former leaders of the CBER. She has served at the FDA as a key advisor to the commissioner and CBER since spring.

“She doesn’t seem to have the requisite experience” for overseeing the pharmaceutical oversight division, said a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She lacks experience in running a major agency. She is not an expert in drug approvals.”

Previous directors of CBER would “be deeply familiar with laws and regulations and the research of drug development”, noted Dr. Janet Woodcock. “Frankly, she has not acquired the sort of resume that former directors who ran CBER have had.”

The drug center has an immense range of responsibilities at the agency, the former commissioner emphasized.

“Everybody just focuses on the novel medication approvals, but the generic drug division authorizes numerous generic drugs. There is also a biosimilars division, over-the-counter program and more, and all of those need to be managed,” Dr. Woodcock said. “The responsibility you overlook, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a significant leadership component to the position, which supervises over 5,000 staff members. “It’s a huge leadership role, if you perform it correctly,” the former official said.

Response and Disputed Initiatives

Regarding concerns about Dr. Høeg's qualifications and whether this selection represents greater collaboration among FDA leaders on vaccines, a press secretary responded that the “concerns stem from incorrect premises”.

“Her resume matches the responsibilities of her role,” the official explained, pointing to the period Høeg spent guiding the agency head on “drug safety and oversight research, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg assumes responsibility for the agency head's recently launched priority voucher program, a disputed expedited therapy clearance system that allegedly troubled her former heads. “How are these drugs being chosen for this voucher program? Who takes the decisions?” Howard questioned. “There’s a lot of confidentiality going on at the regulatory body right now.”

In general, he said, “the Food and Drug Administration looks to be trending towards laxer rules of pharmaceuticals, aside from immunizations.”

Documented Track Record on Immunizations

With immunizations, Dr. Høeg has a clearer, if concerning, track record, critics observe. She authored a study using non-validated crowd-sourced reports to determine the rate of heart inflammation after Covid immunization. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccines are pose a greater threat than they are.

Among her “policy goals” for the current government encompassed revising rules for new vaccines and discontinuing “optional” vaccines, she remarked following the vote on a podcast. At the agency, Dr. Høeg has allegedly proposed excluding adolescent males from receiving Covid vaccinations.

“She is an thorough dogmatist who starts off with her beliefs and tailors the evidence to fit the science in a extremely deceptive, untruthful fashion,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Høeg joined fellow contrarians, {like|